NCT06275659Completed
An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis
Source: ClinicalTrials.gov · Last updated 30 Apr 2025
Brief summary (registry, in English)
CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics. One class of CT-100 components are Digital Neuro-activation and Modulation (DiNaMo TM) components. DiNaMo components target key neural systems (including but not limited to systems related to sensory-, perceptual-, affective-, pain-, attention-, cognitive control, social- and self- processing) to optimally improve a participant's health.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 120 (actual)
- First submitted
- 9 Feb 2024
- Start date
- 4 Dec 2023
- Primary completion date
- 23 Feb 2024
- Lead sponsor
- Click Therapeutics, Inc.
- Diseases
- Atopic dermatitis (eczema), Psoriasis
- NCT number
- NCT06275659
What you commit to
- Study type: Interventional
- Participants enrolled: 120
- From 4 Dec 2023 to the primary completion date, 23 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Initiation or change in primary-disease-specific medication within 30 days prior to entering the study.
- Planning the introduction of new therapies (including studies on psychotherapy, mindfulness, cognitive training or pharmacological treatment) during the 7-week study period.
Other illness
- Severe psychiatric disorder involving a history of psychosis (e.g., schizophrenia, bipolar disorder or severe personality disorders).
- Psychiatric hospitalization in the past 6 months.
- Self-reported substance-use disorder within the past 1 year.
- Currently experiencing a skin infection.
Other
- Pregnant or planning to become pregnant.
- Visual, dexterity or cognitive deficit so severe that it precludes the use of an App-based, reaction-time-based activity per investigator judgment.
- Participation in any research study (including studies on psychotherapy, mindfulness, cognitive training or pharmacological treatment) during the past 3 months.
- Anticipating a change in current pharmacological or psychotherapy treatment regimen during the 7-week study period.
Who the study is looking for
- Fluent in written and spoken English, confirmed by ability to read, understand and sign the informed consent form (ICF).
- Lives in the United States.
- Aged 18 years or older.
- Itch NRS ≥ 4 during screening.
- Meets indication-specific inclusion criteria (see Appendix 1), as reported by the study participant with adequate clinical documentation. (Documentation to be provided to the study team upon request.)
- Has an active email address and is willing and able to receive and respond to email messages.
- Has access to an internet connection during the study duration.
- Willing and able to comply with the study protocol and assessments.
- Is the sole user of an iPhone with an iPhone operating system (OS) 14 or later or a smartphone with an Android OS 10 or later for the duration of the study.
- Is willing and able to receive Short Message Service (SMS) text messages and notifications on their smartphone.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Click Therapeutics Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.